English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/14161
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Citado 0 veces en Web of Knowledge®  |  Pub MebCentral Ver citas en PubMed Central  |  Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Título

Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target

AutorMontero, Juan Carlos; Ocaña, Alberto; Abad, María del Mar; Ortiz-Ruiz, María Jesús; Pandiella, Atanasio; Esparís-Ogando, Azucena
Palabras claveErk5
Breast Cancer
Potential Therapeutic Target
MAPK
Fecha de publicación15-may-2009
EditorPublic Library of Science
CitaciónPLoS ONE 4(5): e5565 (2009)
Resumen[Background]: Breast cancer is the most common neoplasia in women. Even though advances in its treatment have improved disease outcome, some patients relapse. Therefore, attempts to better define the molecular determinants that drive breast cancer cell proliferation may help in defining potential therapeutic targets. Mitogen-activated protein kinases (MAPK) play important roles in tumorigenesis. One of them, Erk5, has been linked to the proliferation of breast cancer cells in vitro. Here we have investigated the expression and prognostic value of Erk5 in human breast cancer.
[Methodology/Principal Findings]: Animal and cellular models were used to study Erk5 expression and function in breast cancer. In 84 human breast tumours the expression of Erk5 was analyzed by immunohistochemistry. Active Erk5 (pErk5) was studied by Western blotting. Correlation of Erk5 with clinicopathological parameters and with disease-free survival in early stage breast cancer patients was analyzed. Expression of Erk5 was detected in most patients, and overexpression was found in 20%. Active Erk5 was present in a substantial number of samples, as well as in tumours from an animal breast cancer model. Overexpression of Erk5 was associated with a decrease in disease-free survival time, which was independent of other clinicopathological parameters of prognosis. Transient transfection of a short hairpin RNA (shRNA) targeting Erk5, and a stable cell line expressing a dominant negative form of Erk5 (Erk5AEF), were used to investigate the influence of Erk5 on drugs used in the clinic to treat breast tumours. We found that inhibition of Erk5 decreased cancer cell proliferation and also sensitized these cells to the action of anti-HER2 therapies.
[Conclusions/Significance]: Overexpression of Erk5 is an independent predictor of disease-free survival in breast cancer, and may represent a future therapeutic target.
Descripción8 páginas, 4 figuras, 4 tablas.
Versión del editorhttp://dx.doi.org/10.1371/journal.pone.0005565
URIhttp://hdl.handle.net/10261/14161
DOI10.1371/journal.pone.0005565.
ISSN1932-6203
Aparece en las colecciones: (IBMCC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
pone.0005565.pdf704,81 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 



NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.